New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
10:00 EDTBEAV, WAIR, THLD, RPRX, RLGY, PXD, MPLX, LNCO, LINE, INFI, CELG, BIIB, BRFS, YUMOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: BE Aerospace (BEAV) initiated with an Outperform at Imperial Capital... BRF Brasil Foods (BRFS) initiated with a Buy at Citigroup... Biogen (BIIB) initiated with a Buy at Brean Capital... Celgene (CELG) initiated with a Buy at Brean Capital... Infinity Pharmaceuticals (INFI) initiated with an Outperform at RBC Capital... LINN Energy (LINE) initiated with a Neutral at Goldman... LINN Energy (LINE) initiated with an Outperform at RW Baird... LinnCo (LNCO) initiated with a Buy at UBS... LinnCo (LNCO) initiated with a Neutral at Credit Suisse... MPLX (MPLX) initiated with a Buy at Citigroup... Matrix Service (MTRX) initiated with a Buy at DA Davidson... Pioneer Natural (PXD) initiated with a Buy at Citigroup... Realogy (RLGY) initiated with a Neutral at Citigroup... Repros Therapeutics (RPRX) initiated with a Buy at Roth Capital... Threshold Pharmaceuticals (THLD) initiated with a Buy at Brean Capital... Wesco Aircraft (WAIR) initiated with an In-Line at Imperial Capital... Yum! Brands (YUM) initiated with an Outperform at Macquarie
News For BEAV;BRFS;BIIB;CELG;INFI;LINE;LNCO;MPLX;PXD;RLGY;RPRX;THLD;WAIR;YUM From The Last 14 Days
Check below for free stories on BEAV;BRFS;BIIB;CELG;INFI;LINE;LNCO;MPLX;PXD;RLGY;RPRX;THLD;WAIR;YUM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 10, 2014
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.
April 9, 2014
17:25 EDTINFIPoint72 Asset lowers passive stake in Infinity Pharmaceuticals to 7.1% from 7.5%
Subscribe for More Information
12:12 EDTCELGMarkman documents appear to favor Celgene, The Street says
Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
April 8, 2014
10:03 EDTRLGYOn The Fly: Analyst Initiation Summary
1st United Bancorp (FUBC) initiated with a Neutral at Macquarie... Avista (AVA) initiated with a Fair Value at CRT Capital... Castlight Health (CSLT) initiated with a Neutral at Goldman... Cempra (CEMP) initiated with an Equalweight at Barclays... Coca-Cola (KO) initiated with a Buy at BTIG... JinkoSolar (JKS) initiated with an Overweight at Barclays... Lumenis (LMNS) initiated with a Buy at Goldman... National Retail Properties (NNN) initiated with an Overweight at Morgan Stanley... PepsiCo (PEP) initiated with a Buy at BTIG... Realty Income (O) initiated with an Underweight at Morgan Stanley... Teekay (TK) initiated with an Outperform at Raymond James... Twitter (TWTR) initiated with a Buy at Janney Capital... Realogy (RLGY) initiated with an Outperform at RBC Capital... Bristow Group (BRS) initiated with an Outperform at Clarkson Capital... Era Group (ERA) initiated with an Outperform at Clarkson Capital... Endurance (EIGI) initiated with a Buy at Craig-Hallum... Tutor Perini (TPC) initiated with an Overweight at Stephens... MannKind (MNKD) initiated with an Outperform at Brinson Patrick... TriCo Bancshares (TCBK) initiated with an Outperform at Fig Partners... Achaogen (AKAO) initiated with an Outperform at Cowen.
09:22 EDTRLGYRealogy initiated with an Outperform at RBC Capital
Target $54.
07:54 EDTYUMYum! Brands testing new Super Chix concept, AdAge reports
Yum Brands will start testing Super Chix, a new concept restaurant, AdAge reports. This week, Super Chix will launch in Arlington, Texas, with a limited menu including chicken sandwiches, chicken tenders, fries, salads and custards. A spokesperson for Yum says the concept "may in the future be considered for international purposes." Reference Link
07:22 EDTBIIBCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
April 7, 2014
07:43 EDTLINEIndependent Petroleum Association of America to hold a conference
Subscribe for More Information
06:15 EDTTHLDThreshold Pharmaceuticals files $150M mixed securities shelf
Subscribe for More Information
April 5, 2014
11:29 EDTBEAVBE Aerospace could climb another 25% in a year, Barron's says
BE Aerospace shares could continue to climb another 25% as the company continues to benefit from favorable trends in aircraft acquisitions, Barron's contends in a feature article. Reference Link
April 4, 2014
10:45 EDTCELGMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
10:02 EDTLINE, LNCOOn The Fly: Analyst Downgrade Summary
Antero Resources (AR) downgraded to Buy from Strong Buy at ISI Group... Cobalt (CIE) downgraded to Buy from Strong Buy at ISI Group... Franklin Resources (BEN) downgraded to Market Perform at Keefe Bruyette... Hasbro (HAS) downgraded to Hold from Buy at Needham... PPL Corp. (PPL) downgraded to Neutral from Outperform at Macquarie... Sonic (SONC) downgraded to Neutral from Buy at Buckingham... Vodafone (VOD) downgraded to Neutral from Buy at Nomura... AutoZone (AZO) downgraded to Neutral from Outperform at RW Baird... Advance Auto Parts (AAP) downgraded to Neutral from Outperform at RW Baird... LinnCo (LNCO) downgraded to Neutral from Buy at Citigroup... LINN Energy (LINE) downgraded to Neutral from Buy at Citigroup... General Mills (GIS) downgraded to Hold from Buy at Argus.
07:42 EDTLNCO, LINELinnCo downgraded to Neutral from Buy at Citigroup
Citigroup downgraded LinnCo (LNCO) to Neutral after resuming coverage of the stock and lowered its price target for shares to $31.50 from $41. Note Citi also downgraded LINN Energy (LINE) to Neutral.
07:41 EDTLINELINN Energy downgraded to Neutral from Buy at Citigroup
Citigroup downgraded LINN Energy to Neutral after resuming coverage of the stock citing a lack of distribution growth. Citi lowered its price target for shares to $32 from $41.50.
06:49 EDTCELGMylan sues Celgene for blocking Thalomid, Revlimid generics, Reuters says
Subscribe for More Information
April 3, 2014
07:05 EDTTHLDThreshold to present results of 2 preclinical studies for combinations of TH-302
Subscribe for More Information
06:28 EDTCELGAtopic dermatitis could bring upside to Regeneron, Celgene, says Citigroup
Citigroup believes Regeneron's (REGN) dupilumab and Celgene's (CELG) Otezla for atopic dermatitis are being overlooked by investors and could provide upside for both names. Citi believes both drugs have good efficacy but adds that dupilumab is more advanced. The firm has a Buy rating on both stocks.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use